NuVasive Appoints Two Members to Board

NuVasive Inc.’s Board of Directors has appointeed Robert F. Friel and Donald J. Rosenberg as independent directors of the company, effective Feb. 12. Friel will serve as a member of the board’s Compensation Committee and Rosenberg will serve as a member of the board’s Compensation Committee and the Nominating and Corporate Governance Committee.

The latest appointments expand NuVasive’s Board from seven to nine directors, eight of whom are independent directors.

“We are pleased to welcome Rob and Don to our Board of Directors as we continue to attract high caliber leaders to further complement the diverse skills of our board,” said Gregory T. Lucier, NuVasive chairman/CEO. “As we continue to grow and mature as a company, their collective years of broad experience across important industries will add a valuable perspective to our company. We appreciate their willingness to serve as directors and look forward to benefitting from their judgment and counsel.”

With more than 35 years of finance and operational experience, Friel currently serves as chairman, CEO and president of PerkinElmer Inc., and has been one of the primary architects of the company’s transformation into a global technology leader focused on improving the health and safety of people and the environment. He previously served as president and chief operating officer of PerkinElmer and as vice chairman and president of PerkinElmer’s Life and Analytical Sciences unit. Prior to that, Friel served as executive vice president and chief financial officer of PerkinElmer with responsibility for business development and information technology in addition to his oversight of finance functions. Previously, he held several senior management positions with AlliedSignal Inc., now Honeywell International. Friel received a Bachelor of Arts degree in economics from Lafayette College and a Master of Science degree in taxation from Fairleigh Dickinson University.

Rosenberg possesses extensive expertise in the areas of corporate governance, compliance, law department management, litigation, securities regulation, intellectual property and competition issues, which he developed over a 40-year career at leading Fortune 500 technology companies. He currently serves as executive vice president, general counsel and corporate secretary of Qualcomm Incorporated, a developer of 3G, 4G and next-generation wireless technologies. In this role, Rosenberg is responsible for overseeing Qualcomm’s worldwide legal affairs including litigation, intellectual property and corporate matters. Qualcomm’s Government Affairs, Corporate Compliance and Internal Audit departments also report to him. Prior to joining Qualcomm, he served as senior vice president, general counsel and corporate secretary of Apple Inc. Prior to that, he was senior vice president and general counsel of IBM Corporation. Rosenberg has served as an adjunct professor of law at New York’s Pace University School of Law, where he taught courses in intellectual property and antitrust law. He is the immediate past national co-chairman of the Board of the Lawyers’ Committee for Civil Rights Under Law. He received a Bachelor of Science degree in mathematics from the State University of New York at Stony Brook and his Juris Doctor from St. John’s University School of Law.

Based in San Diego, Calif., NuVasive develops minimally invasive products for spine surgery. The company offers a portfolio of more than 90 products developed to improve spine surgery and patient outcomes. Its principal procedural solution is its Maximum Access Surgery, or MAS, platform for lateral spine fusion. MAS was designed to provide safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.